Hikma Pharmaceuticals PLC (HKMPF PINK) stock market data APIs
$20.4142
0(0%)
as of November 7, 2025
Try our APIs with
free plan!
Hikma Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Prev. Close
20.4142
Open
20.4142
High
20.4142
Low
20.4142
52 wk Range
20.49-27.98
Market Cap
4 538 M
P/E Ratio
12.2695
Shares Outstanding
221 M
Revenue
3 216 M
EPS
0.5345
Dividends (Yield)
0.041
Beta
0.706
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hikma Pharmaceuticals PLC data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC Fundamental Data
Hikma Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 3 216 M
- EBITDA: 764 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC News
New
Health Care Roundup: Market Talk
Find insight on AstraZeneca, Smith & Nephew, Novo Nordisk and more in the latest Market Talks covering Health Care. Continue Reading View Comments
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
The Ritedose Corporation Ritedose receives FDA approval for TobramycinTobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the first cystic fi...
How Recent Developments Are Rewriting the Story for Hikma Pharmaceuticals
The consensus analyst price target for Hikma Pharmaceuticals has increased slightly, rising from £25.02 to £25.40 in the most recent updates. This adjustment reflects an ongoing reassessment by anal...
FTSE 100 hits another high despite concerns over US government shutdown
The FTSE 100 hit another record high on Wednesday, despite concerns over the US shutdown, as pharmaceutical stocks powered higher, with AstraZeneca up 11% alone. The FTSE 100 index closed up 96.00 po...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
